drugset / Trial / NCT04057833

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

NCT04057833 ↗

Phase 1 Enrolling by invitation 20 enrolled Hospital for Special Surgery, New York Angiocrine Bioscience · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1b investigator-initiated clinical trial that will evaluate the safety and feasibility of E-CEL UVEC® cells with the aim of improving outcomes for patients with full-thickness rotator cuff tears who undergo arthroscopic surgical repair. Allogeneic E-CEL UVEC cells will be delivered to the tendon repair site and to the muscle adjacent to the tendon repair site.

Timeline

Start
2019-11-20
Primary completion
2026-10
Completion
2026-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject E-CEL UVEC Cell therapy — Other